Swapnil Hiremath, MD, MPH, FASN
Staff Nephrologist at the Ottawa Hospital
Associate Professor in the Faculty of Medicine at the University of Ottawa
Associate Scientist in the Clinical Epidemiology Programme at the Ottawa Hospital Research Institute.
Swapnil Hiremath teaches at the University of Ottawa, where he currently works as an Associate Professor in the faculty of Medicine. Clinical teaching includes bedside teaching for students, residents and fellows rotating in the nephrology teaching service at the Ottawa Hospital. In addition, he is part of the faculty involved in teaching renal physiology for first year medical students, as well as problem assisted learning for third year medical students.
Additionally, Dr Hiremath enjoys teaching using novel educational media, such as blogs, and twitter. Along with Joel Topf, he co-created #NephJC, an online, twitter based nephrology journal club, which allows discussion of a research article twice a month. Check out the NephJC home page, the twitter stream, and a published report of their experience. He is also a faculty member for the online educational game, NephMadness and the nephrology social media collective (NSMC) internship.
His primary research interest is in using systematic reviews, meta-analyses and decision-analytic modeling to improve care for patients with hypertension, chronic kidney disease, hemodialysis and patients with acute kidney injury. He has grant funding from the Canadian Insititutes of Health Research, Physician Services Incorporated, The Ottawa Hospital Academic Medical Organization, and other agencies, in the field of contrast AKI and difficult to control hypertension. He has authored 4 book chapters, and more than a 100 papers, details available at this Google Scholar link, or on PubMed here.
He serves on the guidelines task force of Hypertension Canada, on the health behaviours subgroup, as well as being the chair of the resistant hypertension subgroup.
He is the nephrology lead of the Canadian Association of Radiologists consensus guidelines on contrast-induced acute kidney injury, as well as the safe use of gadolinium in patients with kidney disease.